Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (CRBU) is a clinical-stage biopharma leader advancing CRISPR-engineered allogeneic CAR-T cell therapies. This page aggregates official announcements, clinical trial milestones, and strategic developments related to its chRDNA technology platform.
Investors and researchers will find timely updates on Caribou's innovative pipeline programs targeting hematologic cancers and autoimmune diseases. Key focus areas include CB-010 for B-cell malignancies, CB-011 in multiple myeloma, and autoimmune applications of PD-1 knockout therapies.
The repository features press releases on clinical trial data, regulatory progress, intellectual property developments, and strategic collaborations. Content is organized to highlight scientific advancements while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined access to Caribou's latest CRISPR innovations and corporate announcements. Check regularly for updates on allogeneic cell therapy developments and their potential impact on treatment paradigms.
Caribou Biosciences, Inc. (CRBU) reported significant achievements in 2021, including its successful IPO and the initiation of the ANTLER Phase 1 clinical trial for lead candidate CB-010, aimed at treating r/r B-NHL. The company anticipates submitting an IND application for CB-011 for r/r multiple myeloma in 2022. As of December 31, 2021, Caribou has $413.5 million in cash and securities, supporting its allogeneic CAR-T and CAR-NK pipeline. However, the company reported a net loss of $66.9 million for the year.
Caribou Biosciences (NASDAQ: CRBU) announced preclinical data for its allogeneic anti-BCMA CAR-T cell therapy, CB-011, targeting relapsed or refractory multiple myeloma. The data will be showcased at the AACR Annual Meeting 2022, set for April 8-13, 2022, in New Orleans. CB-011 utilizes Cas12a chRDNA technology to prevent immune rejection, focusing on manufacturing an IND application by 2022. The presentation details include the title, presenter, and time, with registered attendees able to access the content online after April 8. Caribou continues advancing its CRISPR-based therapies.
Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz will present at two investor conferences in March 2022. The first event is the Oppenheimer 32nd Annual Healthcare Conference on March 16 at 10:00 am ET. The second is the H.C. Wainwright Gene Therapy and Gene Editing Conference on March 30, with a presentation webcast starting at 7:00 am ET. Webcasts will be available on Caribou's website for 30 days post-event. The company focuses on CRISPR genome editing technology to develop precise therapies for serious diseases.
On February 7, 2022, Caribou Biosciences (Nasdaq:CRBU) announced that its CEO, Rachel Haurwitz, Ph.D., will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17 at 2:20 pm ET. A live webcast will be available on Caribou's website, with an archived version accessible for 30 days post-event.
Caribou specializes in CRISPR genome editing, utilizing advanced technologies, including chRDNAs, for precise gene modifications aimed at developing innovative therapies for serious diseases.
Caribou Biosciences has appointed Dr. Syed Rizvi as chief medical officer, a role aimed at steering its oncology cell therapy pipeline. Dr. Rizvi brings over 20 years of drug development experience, having previously led clinical strategy for CAR-T therapies like ABECMA and BREYANZI. The company plans to disclose initial data from its ANTLER Phase 1 clinical trial for product candidate CB-010 in 2022, file an IND application for CB-011, and select targets for its CAR-NK cell therapy, CB-020. Dr. Rizvi's leadership is anticipated to enhance Caribou’s development efforts.
Caribou Biosciences, Inc. (Nasdaq: CRBU) announced that Rachel Haurwitz, Ph.D., President and CEO, will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 9:45 am ET. The presentation will be available via live webcast on Caribou's website, with an archived version accessible for 30 days post-event. Caribou is advancing its CRISPR genome-editing technology, focusing on developing next-generation CAR-T and CAR-NK cell therapies to treat severe diseases.
Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz will attend investor conferences from November 30 to December 2, 2021. The events include the Piper Sandler 33rd Annual Virtual Healthcare Conference and the Evercore ISI 4th Annual HealthCONx Conference. A fireside chat at the latter is scheduled for December 2, from 4:20 to 4:40 PM ET. Webcasts will be available on Caribou's website for 30 days post-event. Caribou is focused on innovative CRISPR genome editing technologies, particularly using chRDNA for developing advanced therapies.
Caribou Biosciences reported promising advancements in its Q3 2021 financial results, with cash and equivalents of $435.3 million, bolstered by a successful IPO that raised $321.0 million. The company is progressing with its lead candidate, CB-010, in the ANTLER Phase 1 trial for non-Hodgkin lymphoma, aiming to share initial data in 2022. Caribou's proprietary chRDNA technology provides enhanced specificity for genome edits, crucial for developing CAR-T therapies. The firm also welcomed new board members and a chief business officer, enhancing its leadership team.
Caribou Biosciences (Nasdaq: CRBU) announced the appointment of Dara Richardson-Heron to its board and Ruhi Khan as chief business officer. Dr. Richardson-Heron brings over 25 years of healthcare experience, while Ms. Khan contributes 20 years of business development expertise. Both appointments are aimed at advancing Caribou’s allogeneic cell therapies, including the Phase 1 candidate CB-010. The company leverages its chRDNA genome-editing technology to develop CAR-T and CAR-NK therapies targeting hematologic malignancies and solid tumors.
Caribou Biosciences, a leading CRISPR genome-editing biopharmaceutical company, announced that its CEO, Rachel Haurwitz, will present at two upcoming investor conferences. The presentations are scheduled for the Jefferies Gene Therapy/Editing Summit on October 27 and the Barclays Gene Editing & Gene Therapy Summit on November 15. Live webcasts will be available on Caribou's website, with archived versions accessible for 30 days post-event. Caribou is focused on developing next-generation therapies using its proprietary chRDNA technology to enhance genome editing precision.
